Department of Urology, La Paz University Hospital, Madrid, Spain; Instituto de investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.
Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
Eur Urol Focus. 2019 Sep;5(5):799-806. doi: 10.1016/j.euf.2018.02.012. Epub 2018 Mar 7.
The indeterminate multiparametric prostate magnetic resonance image (mpMRI) lesion is one which cannot be classified as "positive" or "negative" for suspected cancer. Currently, there is no consensus on how to manage patients with indeterminate mpMRIs where areas cannot be classified as positives or negatives (Prostate Imaging Reporting and Data System [PI-RADS] 3 or Likert 3).
To define the concept of indeterminate lesion and describe the management strategies that may be adopted for these patients.
A literature search of the PubMed database was performed including the search terms "prostate indeterminate lesions", "PI-RADS 3", "Likert 3", "magnetic resonance imaging", and "prostate cancer".
There is no universally accepted definition of what constitutes an indeterminate lesion on mpMRI. This is partly due to the experience of the reporting radiologist and their willingness to call a lesion indeterminate, knowing that this may have consequences for biopsy decisions. This is also partly due to the significant variation in mpMRI acquisition parameters used between different sites. Strategies for managing the indeterminate lesion include: (1) biopsy, where there is a highly variable prevalence of prostate cancer (PCa), reflecting the differences in clinically significant PCa definitions, mpMRI protocols and interobserver variability in characterization of indeterminate lesions and (2) surveillance, where early results suggest that this strategy may be of value for some selected patients with prostate-specific antigen (PSA) monitoring and/or interval mpMRI. The use of prebiopsy MRI, in conjunction with traditional clinical parameters and secondary biomarkers-nomograms, may allow a more accurate selection of patients who can avoid biopsy.
A strategy of close surveillance based on PSA monitoring and interval mpMRI is a feasible management option for motivated patients with indeterminate mpMRI. This surveillance strategy could result in fewer men needing to undergo biopsy, and although early results are promising, long-term results for such a strategy are awaited.
In some patients who have an MRI scan of their prostate, the scan may identify an area which may or may not contain cancer. This area is typically called the "indeterminate" lesion. In this report, we attempted to define the concept of indeterminate lesion on multiparametric magnetic resonance (mpMRI) and described the strategies that may be performed for these patients. The use of mpMRI in conjunction with traditional clinical parameters may allow more accurate risk stratification and assessment of the need for prostate biopsy.
无法被归类为“阳性”或“阴性”疑似癌症的多参数前列腺磁共振成像(mpMRI)病变为不确定病变。目前,对于无法归类为阳性或阴性(前列腺影像报告和数据系统[PI-RADS] 3 或 Likert 3)的不确定 mpMRI 病变,尚无共识如何管理此类患者。
定义不确定病变的概念,并描述可能适用于这些患者的管理策略。
对 PubMed 数据库进行文献检索,检索词包括“前列腺不确定病变”、“PI-RADS 3”、“Likert 3”、“磁共振成像”和“前列腺癌”。
目前,尚无普遍接受的定义来确定 mpMRI 上的不确定病变。这部分是由于报告放射科医生的经验以及他们愿意将病变归类为不确定,因为他们知道这可能会对活检决策产生影响。这也部分是由于不同地点之间使用的 mpMRI 采集参数存在显著差异。管理不确定病变的策略包括:(1)活检,其前列腺癌(PCa)的患病率差异很大,反映了不同的临床显著 PCa 定义、mpMRI 方案以及对不确定病变的特征描述的观察者间变异性之间的差异;(2)监测,早期结果表明,对于一些具有前列腺特异性抗原(PSA)监测和/或间隔 mpMRI 的特定患者,这种策略可能具有价值。使用活检前 MRI,结合传统临床参数和次要生物标志物-诺莫图,可以更准确地选择可以避免活检的患者。
基于 PSA 监测和间隔 mpMRI 的密切监测策略是有动机的不确定 mpMRI 患者的可行管理选择。这种监测策略可能会减少需要进行活检的男性数量,尽管早期结果很有希望,但仍需等待该策略的长期结果。
在一些接受前列腺磁共振成像(MRI)扫描的患者中,扫描可能会识别出一个可能包含或不包含癌症的区域。这个区域通常被称为“不确定”病变。在本报告中,我们试图定义多参数磁共振成像(mpMRI)上的不确定病变概念,并描述了可能适用于这些患者的策略。mpMRI 结合传统临床参数可实现更准确的风险分层和评估前列腺活检的必要性。